

Michael R. Pence Governor

Jerome M. Adams, MD, MPH State Health Commissioner

DATE:

March 6, 2015

TO:

All Local Health Departments

Attn: Chief Food Inspection Officer

FROM:

Laurie Kidwell, RRT Supervisor

Food Protection Program

SUBJECT:

Hospira, Inc. - RECALL [Drug]

AFFECTED

PRODUCT:

Magnesium Sulfate in 5% Dextrose, Inj., USP

SUMMARY:

Unclassified Recall; The recall is due to confirmed customer reports of an <u>incorrect barcode</u> on the primary bag labeling. The barcode on the overwrap is correct; however, there is potential for the primary container barcode to be mislabeled with the barcode for Heparin Sodium 2000 USP units/1000 mL in 0.9% Sodium Chloride Inj. The product is labeled with the correct printed name on the primary container and overwrap.

The product is packaged in 50/100 mL container bags and sold 24 bags per carton (NDC: 0409-6727-23, Lot

42-120-JT, Expiry 1DEC2015).

The lot was distributed nationwide in the U.S. to wholesalers, distributors and hospitals from October 2014

to January 2015.

SUGGESTED

ACTION:

For consumer inquiry only. For additional assistance, call Stericycle at 1-866-382-9260 between the hours

of 8 a.m. to 5 p.m. ET, Monday through Friday.

Recall -- Firm Press Release

FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

Hospira Issues a Voluntary Nationwide Recall of One Lot of Magnesium Sulfate in 5% Dextrose Injection Due to Incorrect Barcode Labeling

Contact:

Consumer: 1-888-345-4680

1-000-040-400

Media:

224-212-2357

FOR IMMEDIATE RELEASE — March 6, 2015 — LAKE FOREST, III. — Hospira, Inc., (NYSE: HSP) has announced a voluntary recall of one lot of Magnesium Sulfate in 5% Dextrose, Inj., USP, 10 mg/mL (NDC: 0409-



6727-23, Lot 42-120-JT, Expiry 1DEC2015) to the user level due to confirmed customer reports of an incorrect barcode on the primary bag labeling. The barcode on the overwrap is correct; however, there is potential for the primary container barcode to be mislabeled with the barcode for Heparin Sodium 2000 USP units/1000 mL in 0.9% Sodium Chloride Inj. The product is labeled with the correct printed name on the primary container and overwrap.

If the incorrect barcode on Magnesium Sulfate in 5% Dextrose, Inj., USP, 10 mg/ mL is not detected prior to dispensing or administration to a patient, and the product is administered based on the printed name, patient harm is unlikely since the barcode on the overwrap and readable text on the primary container and overwrap are correct. However, if detected, there is the potential for delay in treatment of magnesium sulfate in 5% dextrose, that can result in life-threatening seizures, stroke, cerebral hemorrhage and maternal death, and attendant risks to the fetus, including fetal demise. Administration of the magnesium sulfate drug product to a patient who is prescribed heparin and in whom the magnesium sulfate is contraindicated can result in serious adverse events related to the drug's pharmacologic action and may require medical intervention. Although serious in nature, the likelihood of this risk to occur is low due to the high detectability of this nonconformance. To date, Hospira has not received reports of any adverse events associated with this issue for this lot.

Magnesium sulfate in 5% dextrose injection, USP, is a prescription product administered intravenously for the prevention and control of seizures in preeclampsia and eclampsia, respectively. The product is packaged in 50/100 mL container bags and sold 24 bags per carton (NDC: 0409-6727-23, Lot 42-120-JT, Expiry 1DEC2015). The lot was distributed nationwide in the U.S. to wholesalers, distributers and hospitals from October 2014 to January 2015. Hospira has initiated an investigation to determine the root cause and corrective and preventive actions.

Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine the product immediately. Customers should notify all users in their facility. Customers who have further distributed the recalled product should notify any accounts or additional locations which may have received the recalled product and instruct them if they have redistributed the product to notify their accounts, locations or facilities to the consumer level. Hospira will be notifying its direct customers via a recall letter and is arranging for impacted product to be returned to Stericycle in the United States. For additional assistance, call Stericycle at 1-866-382-9260 between the hours of 8 a.m. to 5 p.m. ET, Monday through Friday. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product.

For clinical inquiries, please contact Hospira using the information provided below.

Hospira Contact	Contact Information	Areas of Support
Hospira Global Complaint Management	1-800-441-4100 (8am-5pm CT, M-F) (ProductComplaintsPP@hospira.com)	To report adverse events or product complaints
Hospira Medical Communications	1-800-615-0187 or medcom@hospira.com (Available 24 hours a day/7 days per week)	Medical inquiries

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

About Hospira

Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, III. Learn more at www.hospira.com.

Hospira Issues a Voluntary Nationwide Recall of One Lot of Magnesium Sulfate in 5% Dextrose Injection Due to Incorrect Barcode Labeling

Photo

MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION, USP

Flexible Plastic Container For Intravenous Use Only

Entries, 1859 hospitalist ere in charlesply despyrated WySds, + Bigls, en av allele primiter blade politike is melle. pomber hong bourne in mode. Ny fivondronan'i Pyrise nine, mpinatry ni mao ilay colon, 4 m, 60, m. Ny fivondron'i Et ao indrindrong armitra dia harmatia.

Pix only

Indicatelypate Major.

When advantaged in procession is allowed began the first part in the procession of the advantage of the first procession of the desired and the first part of the procession of the first part of the first p

a housed army will depropose above for the holisms. Recong Ridden:

6 a to home harder the following impossed a super state, for come to the proper to control in home mind in active placed in early and a following holisms in following his control in home mind in active placed in the superior and proper states of the following his control in active placed in the superior home more stable in the superior home property and property

emphodes flood for ground for a scioud last Lat I as a ground in a serge of a fact a displace of flowflood. For Examples of flowflood, and a fact in provide the second is color, that I at all for \$15 in the color labels of facts from last, account analysis to be to be produce in and all confirms in the color of facts from last, account analysis to fact the fact of the last fact in the fact is the color of the color of

Representation in the England and Health processing and anomalism the commentation of a processing designation of processing process and design to the Statistics of Processing Statistics of the Processing Statistics of Processing Statistics o

now supped D Manufalus Laures of th Openius Rivelon, VIII is appoind as angle for a laure plants constrains as Lauren

mit rante desert à que charada afaire aux a la biblida de co de fin data de sale france de metal de la fill de de con-								
1.5	Total	Test	Management Laters	Morrelledite	and the second of the second			
held les Line Container	Mapenton latin'	Repareira ita	Lesceniusine	Corcossisia	Developpiente i			
\$635 (1771-24 146 rt	S c	\$1.54	15 (4 roya)	Alegebyn!	20 rQ restate			
565: 4501 CE 560 +E	35	IX Sept &	15 [3 (5) (1)	16.7 11 2 121 22	414 ridure Adam			
\$60 (D1) (4 100) FE	≯ i	1472 nE4	THE POSTER	16.7 ef 4 132 ms	#13 PO PROTEIN			
"At Tall this office	Carria Carla Artifation (metalline estetion	etrodescentaritatis kilonosim model kiris	de noma de contraction de contractio	amountain translation	COOK A CONTRACTOR DESCRIPTION AND ADMINISTRA			

warring do not vid ticodic container in beres connections. Sure electuated despetits (Social Control Foundation in Processor history

- The property of the property o

- I Jaco MJ, Berg LIF (Logicus C. May make judge a summer of you are been also growed between the stands have presented at Particle Delay 1154.

 He cannot all foreigness (I. Anale Be Microsoft Berling) by house from a survey stands from place and the 115 for 154 for 154

Refse4.75713

Heapen he, take force, t. 0000 USA

8843222



MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION, USP (0.081 mEq Mg**/mL) 10 mg/mL NDC 0409-6727-23 NDC 0409-6727-23

EACH 100 mL CONTAINS MAGNESIUM SULFATE HEPTAHYDRATE 1 g (EQUIVALENT TO 8.1 mEq MAGNESIUM) AND DEXTROSE, HYDROUS 5 g IN WATER FOR INJECTION. MAY CONTAIN SULFURIC ACID AND/OR SODIUM HYDROXIDE FOR pH ADJUSTMENT.
pH 4.5 (3.5 to 6.5) 333 mOsmol/LITER (CALC.) SINGLE-DOSE CONTAINER. DISCARD UNUSED PORTION. FOR I.V. USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES

RX ONLY A

CONNECTIONS.

ATEX)

CONTAINS DEHP Hospira

PRINTED IN USA IM-1581 (7/07) HOSPIRA, INC., LAKE FOREST, IL 60045 USA



100 mL

NDC 0409-6727-23

MAGNESIUM SULFATE

IN 5% DEXTROSE INJECTION, USP

(0.081 mEq Mg++/mL) 10 mg/mL

TOTAL



Each 100 mL contains magnesium sulfate hoptahydrate 1 g (equivalent to 8.1 mEq magnesium) and doctrost, hydroxis 5 g in water for imection. May contain suffure acid and/or soonum hydroxide for pH agustment.

333 m0smol/Liter (CALC.)

pH 4.5 (3.5 to 6.5.)

DO NOT ADD SUPPLEMENTARY MEDICATION. WHENEVER POSSIBLE USE CENTRAL ROUTE.

Single dose container. For I.V. use. Usual dosage: See insert. Sterile, nonpyrogenic. Use only if solution is clear. After removing the overwrap, check for minote leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired. Must not be used in series connections.

The overwrap is a moisture barrier. Do not remove unit from overwrap until ready for use. Use unit promptly when pouch is opened. Store at 20 to 25°C (68 to 77°F). ISee USP Controlled Room Temperature.) Protect from freezing. See insert.

R ONLY





Printed in USA Hospira, Inc., Lake Forest, IL 60045 USA Hospira

MAGNESIUM SULFATE IN 5% DEXTROSE INJECTION, USP

(0.081 mEq Mg⁺⁺/mL) 10 mg/mL

B WR-0249 (7/07)

	·		
		. :	